Poster Session 4
Daniella Rogerson, MD, MS (she/her/hers)
Resident Physician
University of California San Diego Health
San Diego, CA, United States
Marni B. Jacobs, PhD
University of California, San Diego Health
San Diego, California, United States
Omar Mesina, MD (he/him/his)
Assistant Professor
University of California San Diego Health
San Diego, California, United States
Carolina Diaz Luévano, MPH
University of California San Diego Health
San Diego, California, United States
Ayelet Ruppin-Pham, RN
University of California San Diego Health
San Diego, California, United States
Maryam Tarsa, MD
Professor
University of California San Diego
San Diego, California, United States
Ukachi N. Emeruwa, MD, MPH (she/her/hers)
Assistant Professor/Women's Reproductive Health Research Scholar
University of California, San Diego
San Diego, California, United States
Cynthia Gyamfi-Bannerman, MD, MS (she/her/hers)
Professor and Chair
University of California, San Diego
San Diego, California, United States
Elizabeth Nicole Teal, MD, MPH (she/her/hers)
Assistant Professor, Division of Maternal-Fetal Medicine
University of California, San Diego
San Diego, California, United States
ACOG, SMFM, and USPSTF recommend low dose aspirin (LDA) in patients at high risk for preeclampsia (PreE). While there is increasing attention to LDA prescription, little is known about LDA uptake and adherence. This study examines LDA uptake and adherence among patients prescribed.
Study Design:
This is a retrospective cohort study of patients who delivered at an academic medical center from 9/2022 to 7/2024 and were prescribed or recommended LDA for PreE risk reduction. LDA prescription/recommendation was ascertained through the electronic health record and chart review by a quality improvement nurse. Patients not prescribed LDA or for whom prescribing data was unavailable were excluded. The primary outcome was rate of LDA uptake. Secondary outcomes included LDA adherence and associations between sociodemographic characteristics and uptake. Chi-square and Student’s t-tests were used to compare baseline characteristics and multivariable logistic regression determined strength of association.
Results:
Among 1,715 patients prescribed LDA, 1,213 (70%) answered questions about LDA uptake and adherence at delivery admission: 953 (79%) reported taking LDA and 260 (21%) did not. Among those who took LDA, 307 (32%) had adherence data available: 246 (80%) reported taking LDA every day, 43 (14%) missed some doses, and 18 (6%) missed many doses. Patients who took LDA were older and had higher BMI than those who did not (p >0.05, Table 1). Compared to White patients, patients who identified as Black and/or African American had lower odds of LDA uptake in an unadjusted analysis and when adjusting for maternal age and BMI (OR 0.55, 95% CI 0.34 – 0.87 and aOR 0.54, 95% CI 0.30 – 0.96, Table 2). There was no association between language or insurance and uptake.
Conclusion:
Most patients prescribed LDA for PreE risk reduction took the medication and reported good adherence. However, Black patients indicated lower LDA uptake than White patients. Further studies examining LDA uptake/adherence are needed to understand the root causes of these disparities and identify solutions.
